Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants

The emergence of numerous variants of SARS-CoV-2, the causative agent of COVID-19, has presented new challenges to the global efforts to control the COVID-19 pandemic. Here, we obtain two cross-neutralizing antibodies (7D6 and 6D6) that target Sarbecoviruses’ receptor-binding domain (RBD) with sub-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tingting, Xue, Wenhui, Zheng, Qingbing, Song, Shuo, Yang, Chuanlai, Xiong, Hualong, Zhang, Sibo, Hong, Minqing, Zhang, Yali, Yu, Hai, Zhang, Yuyun, Sun, Hui, Huang, Yang, Deng, Tingting, Chi, Xin, Li, Jinjin, Wang, Shaojuan, Zhou, Lizhi, Chen, Tingting, Wang, Yingbin, Cheng, Tong, Zhang, Tianying, Yuan, Quan, Zhao, Qinjian, Zhang, Jun, McLellan, Jason S., Zhou, Z. Hong, Zhang, Zheng, Li, Shaowei, Gu, Ying, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476643/
https://www.ncbi.nlm.nih.gov/pubmed/34580306
http://dx.doi.org/10.1038/s41467-021-25997-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476643/
https://www.ncbi.nlm.nih.gov/pubmed/34580306
http://dx.doi.org/10.1038/s41467-021-25997-3

Ejemplares similares